中文版 | English
Title

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Author
Corresponding AuthorJuanjuan Zhao
Publication Years
2020-10-15
DOI
Source Title
ISSN
1058-4838
EISSN
1537-6591
Volume71Issue:16
Abstract
["Background. The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated.","Methods. 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed.","Results. Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15-39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006).","Conclusions. Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients."]
Keywords
URL[Source Record]
Indexed By
Language
English
WOS Research Area
Immunology ; Infectious Diseases ; Microbiology
WOS Subject
Immunology ; Infectious Diseases ; Microbiology
WOS Accession No
WOS:000595479200001
Publisher
Important Publications
ESI Highly Cited Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers ; ESI Hot Papers
SUSTech Authorship
Others
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:662
Document TypeJournal Article
Identifierhttps://kc.sustech.edu.cn/handle/2SGJ60CL/125972
DepartmentSchool of Medicine
南方科技大学第二附属医院
Affiliation
1.Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
2.The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health & School of Life Science, Xiamen University, Xiamen 361102, Fujian, China
3.Department for Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
4.School of Public Health, Xiamen University, Xiamen 361102, Fujian, China
5.Department of Critical Care Medicine,Shenzhen Third People’s Hospital, Shenzhen 518112, Guangdong Province, China
6.The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
7.School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China
Recommended Citation
GB/T 7714
Juanjuan Zhao,Quan Yuan,Haiyan Wang,et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019[J]. CLINICAL INFECTIOUS DISEASES,2020,71(16).
APA
Juanjuan Zhao.,Quan Yuan.,Haiyan Wang.,Wei Liu.,Xuejiao Liao.,...&Yang Fu.(2020).Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.CLINICAL INFECTIOUS DISEASES,71(16).
MLA
Juanjuan Zhao,et al."Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019".CLINICAL INFECTIOUS DISEASES 71.16(2020).
Files in This Item:
File Name/Size DocType Version Access License
ciaa344.pdf(626KB)